[Form 4] Varonis Systems, Inc. Insider Trading Activity
Guy Melamed, Chief Financial Officer and Chief Operating Officer of Varonis Systems, Inc. (VRNS), reported the sale of 10,400 shares of Varonis common stock on 08/22/2025. The shares were sold under a Rule 10b5-1 trading plan adopted in 2024 at a weighted-average price of $59.53 per share, with transaction prices ranging from $59.50 to $59.57. After the sale, Melamed beneficially owned 417,497 shares. The Form 4 was submitted and signed by an attorney-in-fact on 08/26/2025. The filer notes willingness to provide detailed per-price sale data upon request.
Guy Melamed, Chief Financial Officer e Chief Operating Officer di Varonis Systems, Inc. (VRNS), ha venduto 10.400 azioni ordinarie di Varonis il 22/08/2025. Le azioni sono state disposte nell'ambito di un piano di negoziazione Rule 10b5-1 adottato nel 2024, a un prezzo medio ponderato di $59,53 per azione, con prezzi delle singole transazioni compresi tra $59,50 e $59,57. Dopo la vendita, Melamed deteneva effettivamente 417.497 azioni. Il Modulo 4 è stato presentato e firmato da un procuratore il 26/08/2025. Il dichiarante si dichiara disponibile a fornire, su richiesta, i dettagli delle vendite per singolo prezzo.
Guy Melamed, Director Financiero y Director de Operaciones de Varonis Systems, Inc. (VRNS), informó la venta de 10.400 acciones ordinarias de Varonis el 22/08/2025. Las acciones se vendieron bajo un plan de negociación Rule 10b5-1 adoptado en 2024, a un precio medio ponderado de $59,53 por acción, con precios por transacción entre $59,50 y $59,57. Tras la venta, Melamed poseía de forma beneficiaria 417.497 acciones. El Formulario 4 fue presentado y firmado por un apoderado el 26/08/2025. El declarante indica su disposición a facilitar, si se solicita, los datos detallados de las ventas por precio.
Guy Melamed, Varonis Systems, Inc. (VRNS)의 최고재무책임자(CFO) 겸 최고운영책임자(COO)는 2025-08-22에 Varonis 보통주 10,400주를 매도했다고 보고했습니다. 해당 주식은 2024년에 도입된 Rule 10b5-1 거래계획에 따라 매도되었으며, 주당 가중평균 가격은 $59.53였고 거래별 가격은 $59.50에서 $59.57 사이였습니다. 매도 후 Melamed는 417,497주를 실질적으로 보유하고 있었습니다. Form 4는 2025-08-26에 대리인이 제출하고 서명했습니다. 제출인은 요청 시 거래별 가격 세부내역을 제공할 의향이 있음을 밝혔습니다.
Guy Melamed, directeur financier et directeur des opérations de Varonis Systems, Inc. (VRNS), a déclaré la vente de 10 400 actions ordinaires Varonis le 22/08/2025. Les actions ont été vendues dans le cadre d'un plan de négociation Rule 10b5-1 adopté en 2024, au prix moyen pondéré de 59,53 $ par action, avec des prix de transaction compris entre 59,50 $ et 59,57 $. Après la vente, Melamed détenait effectivement 417 497 actions. Le formulaire 4 a été soumis et signé par un mandataire le 26/08/2025. Le déclarant se dit disposé à fournir, sur demande, les détails des ventes par prix unitaire.
Guy Melamed, Chief Financial Officer und Chief Operating Officer von Varonis Systems, Inc. (VRNS), meldete den Verkauf von 10.400 Aktien der Varonis-Stammaktien am 22.08.2025. Die Aktien wurden im Rahmen eines im Jahr 2024 eingeführten Rule-10b5-1-Handelsplans verkauft, zum gewichteten Durchschnittspreis von $59,53 je Aktie, mit Transaktionspreisen zwischen $59,50 und $59,57. Nach dem Verkauf besaß Melamed wirtschaftlich 417.497 Aktien. Das Formular 4 wurde am 26.08.2025 von einem Bevollmächtigten eingereicht und unterzeichnet. Der Meldende erklärt sich bereit, auf Anfrage detaillierte Angaben zu den einzelnen Verkaufspreisen zu liefern.
- Sale executed under a Rule 10b5-1 plan, indicating pre-established trading and compliance with insider trading rules
- Substantial post-sale ownership remains: 417,497 shares, maintaining significant alignment with shareholders
- Disclosure includes weighted-average price and price range and offers detailed per-trade information on request, enhancing transparency
- Insider reduced holdings by 10,400 shares, which may be viewed negatively by some investors
- Sale price reflects realized liquidity at $59.53 weighted average, potentially signaling management chose to monetize at current levels
Insights
TL;DR Insider sale of 10,400 shares under a pre-established 10b5-1 plan; sizeable remaining ownership.
Melamed's sale was executed under an existing Rule 10b5-1 plan, which typically signals pre-planned, non-discretionary trading rather than opportunistic timing by management. The reported weighted-average sale price of $59.53 and the post-sale ownership of 417,497 shares indicate the executive retains significant economic exposure to VRNS. For investors, this is a routine liquidity event by an officer rather than a clear signal of changed company prospects.
TL;DR Sale follows compliant governance practices; disclosure is appropriately transparent.
The disclosure states the sale was pursuant to a 10b5-1 plan adopted in 2024 and provides a weighted-average price plus a range of execution prices, with an offer to supply detailed per-trade prices on request. Filing signatures and use of an attorney-in-fact are documented. These elements reflect adherence to standard insider trading disclosure and plan usage practices, supporting transparency and compliance.
Guy Melamed, Chief Financial Officer e Chief Operating Officer di Varonis Systems, Inc. (VRNS), ha venduto 10.400 azioni ordinarie di Varonis il 22/08/2025. Le azioni sono state disposte nell'ambito di un piano di negoziazione Rule 10b5-1 adottato nel 2024, a un prezzo medio ponderato di $59,53 per azione, con prezzi delle singole transazioni compresi tra $59,50 e $59,57. Dopo la vendita, Melamed deteneva effettivamente 417.497 azioni. Il Modulo 4 è stato presentato e firmato da un procuratore il 26/08/2025. Il dichiarante si dichiara disponibile a fornire, su richiesta, i dettagli delle vendite per singolo prezzo.
Guy Melamed, Director Financiero y Director de Operaciones de Varonis Systems, Inc. (VRNS), informó la venta de 10.400 acciones ordinarias de Varonis el 22/08/2025. Las acciones se vendieron bajo un plan de negociación Rule 10b5-1 adoptado en 2024, a un precio medio ponderado de $59,53 por acción, con precios por transacción entre $59,50 y $59,57. Tras la venta, Melamed poseía de forma beneficiaria 417.497 acciones. El Formulario 4 fue presentado y firmado por un apoderado el 26/08/2025. El declarante indica su disposición a facilitar, si se solicita, los datos detallados de las ventas por precio.
Guy Melamed, Varonis Systems, Inc. (VRNS)의 최고재무책임자(CFO) 겸 최고운영책임자(COO)는 2025-08-22에 Varonis 보통주 10,400주를 매도했다고 보고했습니다. 해당 주식은 2024년에 도입된 Rule 10b5-1 거래계획에 따라 매도되었으며, 주당 가중평균 가격은 $59.53였고 거래별 가격은 $59.50에서 $59.57 사이였습니다. 매도 후 Melamed는 417,497주를 실질적으로 보유하고 있었습니다. Form 4는 2025-08-26에 대리인이 제출하고 서명했습니다. 제출인은 요청 시 거래별 가격 세부내역을 제공할 의향이 있음을 밝혔습니다.
Guy Melamed, directeur financier et directeur des opérations de Varonis Systems, Inc. (VRNS), a déclaré la vente de 10 400 actions ordinaires Varonis le 22/08/2025. Les actions ont été vendues dans le cadre d'un plan de négociation Rule 10b5-1 adopté en 2024, au prix moyen pondéré de 59,53 $ par action, avec des prix de transaction compris entre 59,50 $ et 59,57 $. Après la vente, Melamed détenait effectivement 417 497 actions. Le formulaire 4 a été soumis et signé par un mandataire le 26/08/2025. Le déclarant se dit disposé à fournir, sur demande, les détails des ventes par prix unitaire.
Guy Melamed, Chief Financial Officer und Chief Operating Officer von Varonis Systems, Inc. (VRNS), meldete den Verkauf von 10.400 Aktien der Varonis-Stammaktien am 22.08.2025. Die Aktien wurden im Rahmen eines im Jahr 2024 eingeführten Rule-10b5-1-Handelsplans verkauft, zum gewichteten Durchschnittspreis von $59,53 je Aktie, mit Transaktionspreisen zwischen $59,50 und $59,57. Nach dem Verkauf besaß Melamed wirtschaftlich 417.497 Aktien. Das Formular 4 wurde am 26.08.2025 von einem Bevollmächtigten eingereicht und unterzeichnet. Der Meldende erklärt sich bereit, auf Anfrage detaillierte Angaben zu den einzelnen Verkaufspreisen zu liefern.